Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novotech Raises $255 Million to Expand Asia-China Clinical CRO Operations

publication date: Jan 19, 2022

Novotech Health Holdings Pte, a clinical CRO with integrated labs and Phase I facilities, completed a $255 million financing. Novotech is an Asia-Pacific CRO that consists of Novotech in Singapore and Australia and PPC in mainland China. The two companies merged in 2020. Novotech said it would use the funds to pursue M&A that will expand its geographical footprint while also adding data, AI and tech-enabled services. The financing valued Novotech at $3 billion. Novotech offers clinical CRO services for all indications and all clinical trial phases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital